Many of the most prescribed medications in America are to treat pain or lower the risk of heart disease. At the top of that list, according to Medicine.net, are Vicodin, Zocor, and Metformin. Many of these are available for as little as $5 because of the health insurance copay system. The prices of some rare drugs, however, can be hundreds or even thousands of times more expensive.
Prescription expense drug screener GoodRx used the official manufacturer list price to find the most expensive drugs in America. According to Becker’s Hospital Review, GoodRx tracked “drugs filled at pharmacies and drugs that can only be administered by healthcare professionals.” The most expensive drug, GoodRx found, is Zolgensma, used to treat spinal muscular atrophy.
The figures were based on the annualized cost of a typical length of treatment. The analysis pointed out that the price of most of these drugs has remained flat since March. Only Folotyn has had a price increase. It rose 3% between April and July. The course of a Folotyn treatment, which can last weeks, is $817,865 based on the methodology. It is used to treat some patients with T-cell lymphoma, a rare type of cancer.
The most expensive drug, Zolgensma, comes at a one-time cost of $2,125,000. It was approved by the U.S. Food and Drug Administration in 2019. According to the European Medicines Agency: “Zolgensma is a gene therapy medicine for treating spinal muscular atrophy, a serious condition of the nerves that causes muscle wasting and weakness.” Most of these drugs also have serious side effects. These are the 25 most dangerous drugs.
This medication is the only gene treatment for this condition. The treatment’s high price almost certainly reflects the costs to develop it. The drug was developed by pharmaceutical company AveXis. GoodRx points out that most insurance companies do not cover this cost. However, the drug only needs to be administered once. One way Folotyn is more “affordable” is that an insurance company can make payments spread over five years.
Click here for the the average annual cost of the 10 most expensive drugs in America
10. Soliris
> Annual cost based on length of therapy: $678,392
> Manufacturer: Alexion Pharmaceuticals, Inc
> Approved for: Treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome — types of blood disorders
[in-text-ad]
9. Ravicti
> Annual cost based on length of therapy: $695,970
> Manufacturer: Horizon Therapeutics
> Approved for: Managing symptoms of inborn urea cycle disorders that increase ammonia levels in the blood
8. Blincyto
> Annual cost based on length of therapy: $712,672
> Manufacturer: Amgen, Inc
> Approved for: A rare type of acute lymphoblastic leukemia (ALL) — cancer of the blood and bone marrow
7. Brineura
> Annual cost based on length of therapy: $730,340
> Manufacturer: BioMarin Pharmaceuticals
> Approved for: Used to slow the loss of walking in pediatric patients and others with a common form of Batten disease, a neurodegenerative disease
[in-text-ad-2]
6. Folotyn
> Annual cost based on length of therapy: $817,865
> Manufacturer: Acrotech Biopharma
> Approved for: Treatment of patients with relapsed or refractory peripheral T-cell lymphoma, a rare blood cancer
5. Luxturna
> Annual cost based on length of therapy: $850,000
> Manufacturer: Spark Therapeutics
> Approved for: Treatment of biallelic RPE65 mutation-associated retinal dystrophy — an inherited eye disease that leads to vision loss and in some cases blindness
[in-text-ad]
4. Myalept
> Annual cost based on length of therapy: $889,904
> Manufacturer: Aegerion Pharmaceuticals
> Approved for: Used to treat leptin deficiency in patients with generalized lipodystrophy, a rare genetic disorder characterized by severe loss of body fat
3. Danyelza
> Annual cost based on length of therapy: $977,664
> Manufacturer: Y–mAbs Therapeutics, Inc
> Approved for: Treatment of pediatric patients and older patients with high-risk neuroblastoma (a cancer) in the bone or bone marrow
2. Zokinvy
> Annual cost based on length of therapy: $1,032,480
> Manufacturer: Eiger BioPharmaceuticals
> Approved for: Used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and to treat progeroid laminopathies — both rare genetic diseases that cause premature aging and death
[in-text-ad-2]
1. Zolgensma
> Annual cost based on length of therapy: $2,125,000
> Manufacturer: Novartis Gene Therapies
> Approved for: Used to treat children less than 2 years old with spinal muscular atrophy, a genetic disorder that causes muscles to become weak and waste away
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
